Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1828)	11/9/1998 9:54:00 AM
From: trofala	Read Replies (1) \| Respond to of 1894

Nov. 9, 1998--Celsion Corp. (OTC BB:CELN) today announced that it has appointed Peter Gombrich to the board, replacing former director Mel Soule. A seasoned executive with over 30 years experience in the healthcare industry, Gombrich brings to Celsion a proven ability to create and develop successful private and publicly-held medical device companies with over $100 million in annual revenues. Two of these companies yielded a 10-fold return to original investors. ''During his distinguished career in the healthcare industry, Peter Gombrich has forged strong strategic contacts with physicians, companies, and research organizations worldwide,'' commented Celsion President and CEO Spencer Volk. ''His expertise with start-up medical device firms will be of great benefit to Celsion as we prepare to begin clinicals on our breast cancer and BPH treatment systems.'' In 1976 Gombrich co-founded St. Jude Medical, Inc. (NYSE:STJ - news), a world renowned life support medical device company that specializes in the global cardiovascular industry. As executive vice president and subsequently president of the pacemaker division, he oversaw product development as well as St. Jude Medical's corporate evolution as the world's leading heart valve company. During his five years at Medtronic, Inc. (NYSE:MDT - news), the world's leading medical technology company which specializes in implantable and interventional therapies, Gombrich directed Medtronic's sales and marketing efforts leading to the company's early significant growth. After founding Clinicom, Inc. in 1982, Gombrich was instrumental in developing the company as a leader in the bedside clinical information systems industry. After Clinicom was taken public it was subsequently acquired by HBO & Company (NASDAQ:HBOC - news), a major healthcare information systems company that delivers enterprise-wide patient care, clinical, financial, and strategic management software solutions and other services to healthcare organizations worldwide. In 1994 Gombrich founded AccuMed International, Inc. (NASDAQ:ACMI - news), an emerging global leader in integrated, technology-driven cytopathology and microbiology systems. As chairman, president, and chief executive officer, Gombrich oversaw AccuMed's product development and commercialization as well as its strategic alliances with worldwide enterprises. Gombrich grew AccuMed's annual revenues in excess of $20 million and left to pursue the business of InPath, LLC where he currently serves as chief executive officer and chairman. Founded by Gombrich in February 1998 based on technology and biomolecular licenses, InPath develops point-of-care diagnostic systems for cervical, gastrointestinal, and pulmonary markets. The Company has strategic alliances with numerous healthcare companies and world renowned medical professionals and scientists to conduct its research and development, clinical investigations, product design, manufacturing, and marketing....there is more

To: Sigmund who wrote (1828)	11/27/1998 9:16:00 PM
From: Cisco	Read Replies (2) \| Respond to of 1894

Hello Sigmund, Any ideas on where the price is headed? Interesting week. Cisco

To: Sigmund who wrote (1828)	12/3/1998 2:30:00 PM
From: trofala	Read Replies (1) \| Respond to of 1894

Hello Sigmund, this is an interesting turn of events,imo, what do you think,? (With the sale of the micro and if this flies, will accumed have anything left)? Dec. 3 /PRNewswire/ -- Ampersand Medical Group announced today that the company has made an offer to AccuMed International, Inc. (Nasdaq: ACMI - news) to acquire its AcCell™ product line. The offer includes cash plus a royalty and a license back to AccuMed for certain technology owned by Ampersand that may be used on AccuMed's Savant system. ''We are confident that AccuMed will see the value of this offer for its company, shareholders and customers,'' said Peter Gombrich, Chief Executive Officer of Ampersand Medical Group, who has also expressed interest in purchasing AccuMed's TracCell™ product line. ''Having been the founder and former CEO of AccuMed, I fully appreciate the potential of these two product lines. My company believes very strongly this technology will fit well into Ampersand's diagnostic systems and product portfolio.'' The AcCell Cytopathology System is a series of automated computer-assisted microscopy work-stations and software that are integrated with laboratory information systems for the screening and diagnosis of cervical Pap smears and other cytology specimens. AcCell allows for easier analysis of cellular specimens and increases efficiency for cytotechnologists, pathologists, and cytology labs in general. Ampersand is seeking to acquire the AcCell 2000, 2001, and 3000 product lines consisting of hardware and software, as well as all intellectual property pertaining to those technologies, and AccuMed's contracted customer base. ''If we are successful in acquiring these product lines, we will integrate many aspects of the system into other elements of our bio-molecular diagnostic systems which we are bringing to market,'' Gombrich said. ''We will honor all current customer contracts and will attempt to rehire many of the key employees that were laid off by AccuMed in order to assure successful implementation of the system.'' Currently, Ampersand Medical Group is made up of several cytology diagnostic companies. InPath, LLC, a biomolecular medical device company developing point-of-care cytology systems, was the first enterprise to become part of Ampersand. Most recently, Ampersand reached agreement in principle with a French company, Unilog, to acquire its Samba cytology/telemedicine business. Samba has developed and installed extensive telemedicine systems which allow remote analysis of cellular material by medical professionals. Samba has also developed extensive imaging software and hardware systems for invitro (out of body) and invivo (in body) cellular analysis. The company already has over 100 systems in use. Ampersand believes the combination of all these products and technologies from InPath, AccuMed and Samba will provide a fully integrated invitro and invivo diagnostic system for the company, thrusting Ampersand on a fast track for cytological diagnostic technology and services. Ampersand Medical, headquartered in Chicago, is a privately-held business group comprised of a number of diagnostic and therapeutic medical device and systems companies. Ampersand Medical is dedicated to improving the lives of patients by integrating innovative diagnostic and therapeutic technologies to improve the detection, treatment and management of cancer